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SchizophreniaThe Speciﬁc Levels of Functioning Scale (SLOF) has been reported to provide ameasure of social function in
patients with schizophrenia. The aim of thismulti-center studywas to determine convergent validity of the
Japanese version of SLOF, and if cognitive insight would be associated with social function. Fifty-eight pa-
tients with schizophrenia participated in the study. Social function, neurocognition, and daily activity skills
were evaluated by the Social Functioning Scale (SFS), Brief Assessment of Cognition in Schizophrenia
(BACS) and UCSD Performance-based Skills Assessment-Brief (UPSA-B), respectively. We also assessed
cognitive insightwith the Beck Cognitive Insight Scale (BCIS). Signiﬁcant relationshipswere noted between
scores on the SLOF vs. those of the SFS, BACS, UPSA-B, and BCIS. Speciﬁcally, the correlation between per-
formance on the UPSA-B and SLOF scores was signiﬁcantly more robust compared to the correlation be-
tween performance on the UPSA-B and scores on the SFS. Similarly, the correlation between scores on
the BACS and SLOF tended to be more robust than that between the BACS and SFS. Importantly, while
the correlation between scores on the BCIS and SLOF reached signiﬁcance, it was not so between scores
on the BCIS and SFS. The SLOF Japanese version was found to provide a measure of social consequences
in patients with schizophrenia. Importantly, this study is the ﬁrst to indicate the relationship between cog-
nitive insight and social function evaluated by the SLOF. This ﬁnding is consistentwith the observation that
SLOF scores were considerably associated with performances on objective functional measures.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).pidemiology, Translational
iatry, 4-1-1 Ogawa-Higashi,
580; fax: +81 42 346 3569.
. This is an open access article un1. Introduction
Ameliorating psychotic symptoms has been a traditional target in
the treatment of schizophrenia. However, this approach has been re-
ported to only partially improve functional outcomes of patients in
real-world settings (Green, 1996; Green et al., 2000). Consequently,der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic data.
Mean (SD) Range
M/F 31/27
Age, yr 35.9 (9.6) 20–58
Duration, month 148.3 (111.4) 4–396
PANSS 61.1 (20.1) 33–115
Estimated IQ 100.2 (11.8) 69.3–119.8
Medication (CPZ equiv. mg/day) 546.8 (407.7) 5–1730
BACS (z-score in SD unit) −2.0 (2.2) −8.6 to 2.6
UPSA-B 72.4 (18.8) 0–94
SFS 109.4 (26.4) 17–186
SLOF 90.7 (15.7) 42–117
BCIS 8.5 (5.4) −2 to 24
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cognitive function, e.g. several types of memory, executive function,
attention, and verbal ﬂuency, which has been shown to predict social
outcomes more closely than do psychotic symptoms (Harvey, 2009;
Wykes et al., 2011). TheMeasurement andTreatmentResearch to Im-
prove Cognition in Schizophrenia (MATRICS) Consensus Cognitive Bat-
tery (MCCB) (Nuechterlein and Green, 2006) and the Brief Assessment
of Cognitive Function in Schizophrenia (BACS) (Keefe et al., 2004) rep-
resent assessment tools to evaluate such neurocognitive functioning.
As a level of functional outcome mediating cognitive function
(primarymeasure) and social function, scales to assess functional ca-
pacity (for daily living activities), or co-primary measures, have been
implemented (Green et al., 2008). The UCSD Performance-based
Skills Assessment-Brief (UPSA-B) (Mausbach et al., 2007) is one of
such measures broadly used to evaluate everyday functioning. This
scale represents a performance-based scale of everyday functioning,
whose Japanese version has been developed and validated
(Sumiyoshi et al., 2014, 2011).
For the assessment of social function, attempts have been made to
determine which tools can adequately measure “real-world functional
outcomes” linked to neurocognition and daily activity skills (Harvey
et al., 2011; Leifker et al., 2011). Accordingly, theValidation of Everyday
Real-World Outcomes (VALERO) initiative supported by the Rand ex-
pert panel selected the Quality of Life Scale (QLS), Social Functioning
Scale (SFS), Speciﬁc Levels of Functioning Scale (SLOF), Social Behavior
Schedule, Independent Living Skills Schedule, and Life Skills Proﬁle as
appropriate measures of social, residential, and vocational outcomes
(Leifker et al., 2011). Speciﬁcally, Harvey et al. (2011) found the SLOF,
among other social function scales discussed by the RAND panelists,
best predicts performances on theMCCB, UPSA-B, and the advanced ﬁ-
nances subscale of the Everyday Functioning Battery.
The SLOF has been developed as an interview-basedmultidimen-
sional assessment measure of social outcomes, including interper-
sonal, vocational and independent-living domains (Schneider and
Struening, 1983). To accommodate cross-cultural adaptability of
functional outcomemeasures, its original (English language) version
has been translated into other languages for international use, e.g.
(Mucci et al., 2014). Although we have developed and validated
Japanese versions of the SFS Individuals' version modiﬁed for the
MATRICS-PASS (SFS-PASS) (Sumiyoshi et al., 2015), the development
and validation of the SLOF Japanese version has been awaited, in line
with the growing interest in global clinical trials.
Impairment of metacognition, or the ability to think about think-
ing, has been suggested to be associated with some functional out-
comes, e.g. cognitive function (neuropsychological performance)
(Lysaker et al., 2010), functional capacity (everyday functioning) as
measured by the UPSA (Lysaker et al., 2011), and quality of life as
measured by the QLS (Lysaker et al., 2010) in patients with schizo-
phrenia. Among the domains of metacognition, cognitive insight
has been conceptualized as the mental processes involved in self re-
evaluation of anomalous experiences and speciﬁc misinterpretations
(Beck et al., 2004). In this respect, the Beck Cognitive Insight Scale
(BCIS) (Beck et al., 2004) has been developed to evaluate self-
reﬂectiveness and self-certainty in individuals with psychiatric con-
ditions. The Japanese version of the BCIS was developed based on
the original version, and its validity has been conﬁrmed in patients
with schizophrenia (Uchida et al., 2009).
Although the lack of clinical insight (awareness of the illness), a
core feature of schizophrenia, has been suggested to inﬂuence out-
come (Durand et al., 2015), limited information is available about
whether cognitive insight is related to real-world outcomes in schizo-
phrenia. Itwashypothesized that cognitive insightwould be associat-
ed with social function, particularly when assessed with objective
(interview-based) measures, such as the SLOF, but not subjective
(self-reported) measures, such as the SFS. Therefore, the presentstudy was conducted to determine convergent validity of the
Japanese version of the SLOF, and if cognitive insightwould be related
to social function, as measured by the SLOF.
2. Methods
2.1. Subjects
This was a multi-center collaborative study, whose design, char-
acteristics of participants and other information have been registered
(UMIN ID: 000,012,671). Fifty-eight Japanese patients with schizo-
phrenia were recruited at 10 participating institutions throughout
Japan, i.e. Hokkaido University, Keio University, Tokyo Women's
Medical University, Showa University, Nara Medical University,
Kansai University, Oita University, University of Occupational and En-
vironmental Health, Hizen Psychiatric Center, and National Center of
Neurology and Psychiatry. Diagnosis was made based on DSM-IV-TR
criteria by experienced psychiatrists using all available information.
Patients known to be abusing alcohol or illicit drugs, or thosewith ep-
ilepsy, brain damage, or neurologic disorders were excluded.
Demographic data of these subjects are presented in Table 1. Ap-
proximately half of them were female. All patients were taking anti-
psychotic drugs. Written informed consent was obtained from all
participants. The study protocol was approved by the ethics commit-
tees of participating institutions.
2.2. Assessment procedures
Before the study was started, all raters received extensive training
in performing the assessments, according to the procedure previously
reported (Strassnig et al., 2015).
2.2.1. Social function measures
2.2.1.1. SLOF. In this study, the abbreviated version of the SLOF,
consisting of the following domains, was used, according to the recent
literature (Durand et al., 2015; Sabbag et al., 2011, 2012; Strassnig et al.,
2015); Interpersonal Functioning (e.g., initiating, accepting and main-
taining social contacts; effectively communicating), independent par-
ticipation in Everyday Activities (shopping, using telephone, paying
bills, use of leisure time, use of public transportation), and Vocational
Functioning (e.g., employable skills, level of supervision required to
complete tasks, ability to stay on task, completes tasks, punctuality).
For the purpose of this study, we examined only summary scores
based on these three domains, as previously reported (Sabbag et al.,
2011). Some of the subscales of the SLOF, e.g. the social acceptability
and personal care subscales, were not included in calculation of the
total score, based on the suggestions by the Rand Panel, as described
in previous studies (Durand et al., 2015; Sabbag et al., 2011; Strassnig
et al., 2015).
Table 2
Correlations between scores of clinical measures (Pearson's R).
SLOF SFS BACS UPSA-B BCIS PANSS
SLOF ― .557 ⁎⁎ .564 ⁎⁎ .654 ⁎⁎ .300 ⁎ −.591 ⁎⁎
SFS ― .282 ⁎ .342 ⁎⁎ .171 −.269 ⁎
BACS ― .738 ⁎⁎ .354 ⁎⁎ −.532 ⁎⁎
UPSA-B ― .267 ⁎ −.607 ⁎⁎
BCIS ― −.176
BACS, Brief Assessment of Cognition in Schizophrenia.
BCIS, Beck Cognitive Insight Scale.
PANSS, Positive and Negative Syndrome Scale.
SFS, Social Functioning Scale.
SLOF, Social Functioning Scale.
UPSA-B, UCSD Performance-based Skills Assessment-Brief.
⁎ p b 0.1.
⁎⁎ p b 0.01.
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patient and informant; interviewer-rated scores of the SLOFwas used
as an objective measure of social function (Sabbag et al., 2011;
Strassnig et al., 2015).
The SLOF Japanese version (Sumiyoshi and Sumiyoshi, 2012) was
developed based on the original version. The translated version has
been approved by developers after conducting independent forward
and back translations, reconciliation, and pilot testing on patients.
2.2.1.2. SFS. The SFS-PASSwasused to evaluate overall social function-
ing. This scale was designed by theMATRICS-Psychometric and Stan-
dardization Study (MATRICS-PASS) (Kern et al., 2008; Nuechterlein
et al., 2008) for the validation study of theMCCB. It comprises the So-
cial Functioning Scale Individuals' version (Birchwood et al., 1990;
Nemoto et al., 2008). The SFS-PASS, consisting of 7 domains, assesses
social competence by asking subjects' status or activities. Data were
collected from the participants' self-rating/reports. To enhance the
accuracy of self-rating, most items were accompanied by anchor
points (frequencies). For example, the degree of activities of ‘Visiting
friends’ is well deﬁned as ‘Never’=0 times [0 point]; Rarely =more
than once in recent 3 months [1]; Sometimes =more than once in a
month [2]; Often = more than once in a week [3]. The associations
between ratings with this Japanese version of the SFS (self-reported)
and theMCCB composite score have been reported (Sumiyoshi et al.,
2015; Sumiyoshi and Sumiyoshi, 2015).
2.2.2. Functional capacity measure
2.2.2.1. UPSA-B. The Japanese version of the UPSA-B (Mausbach et al.,
2007) was used to assess everyday functioning. This battery consists
of Finances and Communication subdomains. The former includes
basic ﬁnancial skills such as counting change or extracting informa-
tion from a bill payment. The latter evaluates communicative ability
such as speaking on the phone or rescheduling an appointment. All
the tasks are role-played. Each task score is summed by subscales
and then transformed to standard scores (0–50). The total score is
the sum of the subscale standard scores (0–100). The Japanese ver-
sion was developed based on the international version of the UPSA-
B,with somemodiﬁcations to adjust for differences in everyday living
skills in Japan (Sumiyoshi et al., 2011). The equivalency to its original
version and validity have been conﬁrmed (Sumiyoshi et al., 2014).
2.2.3. Neurocognition
2.2.3.1. Brief Assessment of Cognition in Schizophrenia (BACS). Cognitive
assessment was conducted by the Japanese version of the Brief As-
sessment of Cognition in Schizophrenia (BACS) (Kaneda et al.,
2013), based on the original version (Keefe et al., 2004). The cognitive
domains included in the BACS are verbal memory, workingmemory,
motor speed, verbal ﬂuency, attention, and executive function. The
primarymeasure from each test of the BACSwas standardized by cre-
ating z-scores whereby the mean score of Japanese healthy controls
was set to zero and the standard deviation set to one (Kaneda et al.,
2013). A composite score was calculated by averaging all z-scores of
the six primary measures.
2.2.4. Cognitive insight
Cognitive insight (metacognition) was measured by the BCIS
Japanese version (Uchida et al., 2009). It is a self-report instrument
consisting of 15 items rated on a 4-point scale (0, do not agree at
all; to 3, agree completely).
2.2.5. Psychopathology
The severity of symptomswasmeasured by the Positive and Neg-
ative Syndrome Scale (PANSS) Japanese version (Kay et al., 1987).2.2.6. Statistical analyses
SPSS ver. 22.0 was used for statistical analyses. Test–retest reli-
ability of the SLOF scores was examined by Kendall's rank correlation
coefﬁcient. The internal consistency of the SLOF were measured by
Cronbach alpha coefﬁcients. Pearson's correlation coefﬁcients with
scores of the SFS, BACS, and UPSA-Bwere obtained to test the validity
of the SLOF. Also, the relationships between summary scores of the
SLOF and those of the BCIS or PANSS were evaluated by the Pearson's
method. Signiﬁcance was considered when p-value was less than
0.05.
3. Results
3.1. Demographic data
Table 1 shows demographic backgrounds of patients. All were
medicated. Generally, they were relatively chronic, with mean dura-
tion of illness N12 yr. Psychometric variableswere normally distribut-
ed. Mean (SD) of SLOF subscale scores were: Interpersonal
Functioning, 21.8 (6.0); Everyday Activities, 48.1 (7.1); and Vocational
Functioning, 20.8 (5.5).
3.2. Reliability
Cronbach alpha for the SLOF Japanese version was 0.80.
3.3. Validity
As shown in Table 2, signiﬁcant positive correlations were ob-
served between scores on the SLOF and those of the SFS, BACS,
UPSA-B, and BCIS. Also, SLOF scores were negatively correlated with
PANSS scores. A signiﬁcant associations were also noted between
the SLOF scores vs. PANSS Positive (R=−0.345, p b 0.01) and Nega-
tive (R=−0.690, p b 0.001) subscale scores.
Further analysis, with z-transformation of correlation coefﬁcients,
indicated that the correlation between performance on the UPSA-B
and SLOF scoreswas signiﬁcantlymore robust compared to the corre-
lation between performance on the UPSA-B and SFS scores (z= 2.30,
p b 0.05). Similarly, the correlation between scores on the BACS and
SLOF tended to be more robust than that between the BACS and SFS
(Z = 1.89, P = 0.059).
Importantly, while the correlation between scores on the BCIS and
SLOF reached signiﬁcance, it was not so between scores on the BCIS
and SFS (Table 2, Fig. 1).
4. Discussion
The results of this study suggest the validity of the SLOF Japanese
version in terms of the relationship with SFS scores, another social
Fig. 1. Correlations between cognitive insight, measured by the Beck Cognitive Insight Scale (BCIS) vs. social function,measured by the Speciﬁc Levels of Functioning Scale (SLOF) or
Social Function Scale for the MATRICS-PASS (SFS).
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and UPSA-B (functional capacity), in patients with schizophrenia.
Its internal consistency was found to be acceptable. Importantly, we
have provided the ﬁrst data indicating a positive correlation between
cognitive insight and real-world outcomes, as measured by the SLOF.
The SLOF (English version) is recommended as one of the “real-
world functional outcomes” measures (Durand et al., 2015; Sabbag
et al., 2011, 2012; Schneider and Struening, 1983; Strassnig et al.,
2015), which has been shown to be closely linked to cognitive function
and capacity of daily activity (Harvey et al., 2011). The signiﬁcant cor-
relations with scores on the SFS [another of the recommended real-
world outcome measures (Leifker et al., 2011)], UPSA-B, and BACS in
the current study indicate convergent validity of the SLOF Japanese ver-
sion. Speciﬁcally, the association with SFS scores suggest that the SLOF
is useful as a measure of social function, or real-world functional out-
comes. Further, the ability of the SLOF to predict scores on the UPSA-
B and BACS, reported here, is consistent with results in the VALERO
Study (Harvey et al., 2011) with a similar set of performance-based
measures, e.g. UPSA-B and MCCB. In fact, cognitive function evaluated
by the BACS used here has been shown to correlate with performance
on the MCCB Japanese version (Kaneda et al., 2013).There was a difference in the degree of association with the
performance-based measures (UPSA-B, BACS) between the SLOF
and SFS (Fig. 1). Themore robust associations for the SLOF can be ex-
plained by the fact that it was objectively rated (interview-based)
while patients self-reported for the SFS. These results are similar to
previous observations (Durand et al., 2015) that observer-, but not
self-rated functional status was correlated with performance on the
MCCB and UPSA-B in patients with schizophrenia, although our
data indicate weak, but signiﬁcant correlations between SFS scores
vs. performances on the UPSA-B and BACS.
Toour knowledge, thepresent study is theﬁrst to report a signiﬁcant
relationship between social function, measured by the SLOF, and cogni-
tive insight, assessed by the BCIS. So far, several studies have sought to
relate meta-cognition and cognitive function (neuropsychological per-
formance) or functional capacity in subjects with schizophrenia. Thus,
Lysaker et al. (2010) observed positive correlations between “mastery”,
an ability to work through one's representativeness/mental states, as
evaluated by the Metacognition Assessment Scale, and cognitive func-
tion, e.g. attention/information processing, learning memory, and exec-
utive function. The same group of investigators (Lysaker et al., 2011)
also found this aspect of meta-cognition predicted performance on the
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tween SLOF and BCIS scores, observed in the present study, indicates
the association between some types of meta-cognition and functional
outcomes in patients with schizophrenia.
The positive relationship between cognitive insight and social
function evaluated by the SLOF (interviewer-rated), but not SFS
(self-reported) is consistent with the observation that ratings with
the former scale were more strongly associated with performances
on objective functionalmeasures (i.e. BACS andUPSA-B). This ﬁnding
also point to the usefulness of objective ratings of social function
measures, as has been suggested (Durand et al., 2015).
The negative correlations between SLOF scores vs. scores on the
PANSS (Total and Positive andNegative subscales) indicate the sever-
ity of psychotic symptoms affect social function. So far, the associa-
tions between positive (Galderisi et al., 2014) and negative
(Robertson et al., 2014; Strassnig et al., 2015) symptoms vs. SLOF
scores have been reported. Our ﬁndings are consistent with these
previous observations, and provide additional evidence that overall
psychiatric status, including positive symptoms, may be related to
real-world functional outcomes in patients with schizophrenia.
The limitations of this study include the relatively small number
of subjects and the cross-sectional nature. For example, it may be
worthwhile to see if meta-cognition would be a determinant of
long-term functional outcomes in individuals with schizophrenia-
spectrum disorders.
In summary, the results of this study suggest that the SLOF
Japanese version provides a measure of social consequences in pa-
tients with schizophrenia, indicating universality of this real-world
functional outcomes scale. Importantly, we have provided the ﬁrst
evidence for a relationship between cognitive insight and social func-
tion evaluated by the SLOF. This ﬁnding is consistent with the obser-
vation that scores on this social outcome scale were considerably
associated with performances on objective functional measures
(BACS, UPSA-B).
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